Augmented therapy improves outcomes for children with highrisk Wilms tumor

Augmenting standard therapy with additional agents prolonged EFS for children with favorable histology Wilms’ tumor who had loss of heterozygosity of chromosomes 1p and 16q, according to results of two phase 3 Children’s Oncology Group studies.Approximately 5% to 6% of children with favorable histology Wilms’ tumor have this chromosomal abnormality, which is associated with a greater risk for relapse, according to study background.